Trial Profile
A Phase 3, Randomized, Double-blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Cefepime/zidebactam (Primary) ; Meropenem
- Indications Pyelonephritis; Urinary tract infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Wockhardt
- 16 May 2023 Planned End Date changed from 1 Sep 2023 to 1 May 2024.
- 16 May 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Apr 2024.
- 19 Aug 2022 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.